



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
#26/F
JUL 25 2003
7/30/03
CH CENTER 1600/2900
XO

In re application of:

Upasani *et al.*

Appl. No.: 09/321,882

Filed: May 28, 1999

For: **Neuroactive Steroids of the
Androstane and Pregnane Series**

Confirmation No.: 7179

Art Unit: 1616

Examiner: Badio, B. P.

Atty. Docket: 1483.0130002/JMC/BEC

**Amendment And Reply Under 37 C.F.R. § 1.111 and in the Revised
Format of the Pre-OG Notice Dated January 31, 2003**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated January 23, 2003, Applicants submit the following Amendment and Remarks. This Amendment is provided in the format approved in the pre-OG Notice dated January 31, 2003, entitled, "Amendments In A Revised Format Now Permitted," and in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.